Potential Combination Therapy For Metastatic Breast Cancer
- A global pharmaceutical client was in the process of developing a new combination therapy for HR+/HER2+ metastatic breast cancer (MBC) and required a thorough understanding of the dynamics across different patient groups
- To evaluate the effectiveness, safety, and patient outcomes of HR+/HER2+ MBC therapy, a novel targeted treatment for advanced cancer, through secondary research methods
- Conducted comprehensive desk research, analyzing data from sources including:
- – Academic databases (e.g., PubMed, Cochrane Library, Embase, Scopus)
- – Peer-reviewed oncology journals
- – Government health agencies (e.g., NCI, FDA)
- – Conference proceedings (e.g., ASCO, ESMO)
- – Industry and pharmaceutical company reports
- To address any gaps and corroborate the information derived from secondary sources, we conducted expert interviews with oncologists and patient groups to validate and gain a deeper understanding of the current landscape of breast cancer therapies
- This approach revealed significant insights into the acceptance rate of the new combination therapy, influenced by the gathered evidence
- These findings helped the pharmaceutical company identify crucial insights to determine the next steps for ensuring optimal patient support and drug safety. The research expedited decision-making and provided a clear direction for improving the therapy
